FI111519B - Menetelmä sellaisen tabletin valmistamiseksi, joka sisältävää vaikuttavana aineena dikloorimetyleenifosfonihappoa - Google Patents

Menetelmä sellaisen tabletin valmistamiseksi, joka sisältävää vaikuttavana aineena dikloorimetyleenifosfonihappoa Download PDF

Info

Publication number
FI111519B
FI111519B FI945313A FI945313A FI111519B FI 111519 B FI111519 B FI 111519B FI 945313 A FI945313 A FI 945313A FI 945313 A FI945313 A FI 945313A FI 111519 B FI111519 B FI 111519B
Authority
FI
Finland
Prior art keywords
active ingredient
tablet
weight
tablets
clodronic acid
Prior art date
Application number
FI945313A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI945313A (fi
FI945313A0 (fi
Inventor
Walter Preis
Bernd Muesel
Guenter Neugebauer
Rolf-Dieter Gabel
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25927331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI111519(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE9307393U external-priority patent/DE9307393U1/de
Priority claimed from DE19934322057 external-priority patent/DE4322057A1/de
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of FI945313A0 publication Critical patent/FI945313A0/fi
Publication of FI945313A publication Critical patent/FI945313A/fi
Application granted granted Critical
Publication of FI111519B publication Critical patent/FI111519B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI945313A 1993-05-15 1994-11-11 Menetelmä sellaisen tabletin valmistamiseksi, joka sisältävää vaikuttavana aineena dikloorimetyleenifosfonihappoa FI111519B (fi)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE9307393 1993-05-15
DE9307393U DE9307393U1 (de) 1993-05-15 1993-05-15 Tablette mit verbesserter Bioverfügbarkeit, enthaltend Dichlormethylendiphosphonsäure als Wirkstoff
DE4322057 1993-07-02
DE19934322057 DE4322057A1 (de) 1993-07-02 1993-07-02 Tablette mit verbesserter Bioverfügbarkeit enthaltend Dichlormethylendiphosphonsäure als Wirkstoff
EP9301967 1993-07-24
PCT/EP1993/001967 WO1994026310A1 (de) 1993-05-15 1993-07-24 Tablette mit verbesserter bioverfügbarkeit enthaltend dichlormethylendiphosphonsäure als wirkstoff

Publications (3)

Publication Number Publication Date
FI945313A0 FI945313A0 (fi) 1994-11-11
FI945313A FI945313A (fi) 1994-12-13
FI111519B true FI111519B (fi) 2003-08-15

Family

ID=25927331

Family Applications (1)

Application Number Title Priority Date Filing Date
FI945313A FI111519B (fi) 1993-05-15 1994-11-11 Menetelmä sellaisen tabletin valmistamiseksi, joka sisältävää vaikuttavana aineena dikloorimetyleenifosfonihappoa

Country Status (25)

Country Link
US (1) US5650168A (pl)
EP (2) EP0697890A1 (pl)
JP (1) JP3699110B2 (pl)
KR (1) KR100263284B1 (pl)
CN (1) CN1041797C (pl)
AT (2) ATE128363T1 (pl)
AU (1) AU687744B2 (pl)
BR (1) BR9307859A (pl)
CA (1) CA2162470C (pl)
CZ (1) CZ287984B6 (pl)
DE (1) DE59300688D1 (pl)
DK (1) DK0625355T5 (pl)
ES (1) ES2065313T5 (pl)
FI (1) FI111519B (pl)
GR (2) GR940300095T1 (pl)
HU (1) HU220872B1 (pl)
IL (1) IL106743A (pl)
NO (1) NO307548B1 (pl)
NZ (1) NZ254765A (pl)
PL (1) PL173026B1 (pl)
RU (1) RU2134103C1 (pl)
SK (1) SK281193B6 (pl)
TW (1) TW350772B (pl)
UA (1) UA39884C2 (pl)
WO (1) WO1994026310A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94926C (fi) 1993-11-12 1995-11-27 Leiras Oy Menetelmä klodronaattivalmisteen valmistamiseksi
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
FI109088B (fi) * 1997-09-19 2002-05-31 Leiras Oy Tabletti ja menetelmä sen valmistamiseksi
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
SE9901272D0 (sv) * 1999-04-09 1999-04-09 Astra Ab New improved formulation
CZ289261B6 (cs) * 2000-07-11 2001-12-12 Léčiva, A.S. Tableta vyrobitelná přímým tabletováním, obsahující aktivní látku kyselinu 4-amino-1-hydroxybutyliden-1,1-bisfosfonovou, a způsob její výroby
US8163306B2 (en) * 2003-09-19 2012-04-24 Sun Pharma Advanced Research Company Oral drug delivery system
US10213387B2 (en) 2003-09-19 2019-02-26 Sun Pharma Advanced Research Company Ltd. Oral drug delivery system
US10226428B2 (en) 2003-09-19 2019-03-12 Sun Pharma Advanced Research Company Ltd. Oral drug delivery system
US7151400B2 (en) * 2004-07-13 2006-12-19 Taiwan Semiconductor Manufacturing Company, Ltd. Boost-biased level shifter
CN100370972C (zh) * 2006-01-10 2008-02-27 北京申科联华科技有限公司 一种具有益气养阴、活血复脉功效的片剂及制备方法
CA2694638A1 (en) * 2007-08-02 2009-02-05 Teijin Pharma Limited Preventive or therapeutic agent for diseases caused by abnormal bone metbolism
WO2009122431A2 (en) * 2008-02-15 2009-10-08 Sun Pharma Advanced Research Company Ltd., Oral controlled release tablet

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2813121A1 (de) * 1977-03-29 1978-10-12 Procter & Gamble Verwendung von dichlormethan-diphosphonatverbindungen bei der bekaempfung von collagen-erkrankungen und zur wundheilung
US4634691A (en) * 1980-10-07 1987-01-06 The Procter & Gamble Company Method for inhibiting tumor metastasis
US4517179A (en) * 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
ATE60711T1 (de) * 1986-12-20 1991-02-15 Boehringer Mannheim Gmbh Clodronat-haltige arzneimittel und verfahren zur herstellung derselben.
DE3804686A1 (de) * 1988-02-15 1989-08-24 Henkel Kgaa Arzneimittel mit einer kombination von cytostatika bzw. hormontherapeutika und phosphonoderivaten
FR2629716B1 (fr) * 1988-04-07 1991-07-19 Sanofi Sa Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique
FI83421C (fi) † 1989-06-21 1991-07-10 Huhtamaeki Oy Foerfarande foer framstaellning av farmakologiskt anvaendbara metylenbisfosfonsyraderivat.
DK0573604T3 (da) * 1991-02-26 1995-05-29 Procter & Gamble Pharma Fremgangsmåde til behandling af osteoporosis
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
AU5953894A (en) * 1992-12-23 1994-07-19 Merck & Co., Inc. Bisphosphonate/estrogen therapy for treating and preventing bone loss

Also Published As

Publication number Publication date
IL106743A0 (en) 1993-12-08
FI945313A (fi) 1994-12-13
NO307548B1 (no) 2000-04-25
PL173026B1 (pl) 1998-01-30
JPH08509697A (ja) 1996-10-15
HUT70214A (en) 1995-09-28
GR940300095T1 (en) 1995-01-31
GR3017547T3 (en) 1995-12-31
SK4895A3 (en) 1997-01-08
CZ287984B6 (cs) 2001-03-14
JP3699110B2 (ja) 2005-09-28
DK0625355T4 (da) 2003-10-06
AU4702093A (en) 1994-12-12
CA2162470C (en) 1998-06-16
KR100263284B1 (ko) 2000-08-01
FI945313A0 (fi) 1994-11-11
ES2065313T1 (es) 1995-02-16
HU9403160D0 (en) 1995-02-28
EP0625355A1 (de) 1994-11-23
KR960702322A (ko) 1996-04-27
IL106743A (en) 1999-11-30
CA2162470A1 (en) 1994-11-24
ES2065313T3 (es) 1995-12-01
CN1041797C (zh) 1999-01-27
HU220872B1 (en) 2002-06-29
NO944405D0 (no) 1994-11-17
AU687744B2 (en) 1998-03-05
PL307133A1 (en) 1995-05-02
RU2134103C1 (ru) 1999-08-10
ES2065313T5 (es) 2004-01-01
EP0697890A1 (de) 1996-02-28
WO1994026310A1 (de) 1994-11-24
CZ10095A3 (en) 1995-10-18
BR9307859A (pt) 1996-01-09
NZ254765A (en) 1997-02-24
SK281193B6 (sk) 2001-01-18
NO944405L (no) 1994-11-24
ATE128363T1 (de) 1995-10-15
CN1095267A (zh) 1994-11-23
EP0625355B2 (de) 2003-06-25
UA39884C2 (uk) 2001-07-16
EP0625355B1 (de) 1995-09-27
DK0625355T5 (da) 2003-12-01
US5650168A (en) 1997-07-22
AT128U1 (de) 1995-03-27
DK0625355T3 (da) 1995-12-27
TW350772B (en) 1999-01-21
DE59300688D1 (de) 1995-11-02

Similar Documents

Publication Publication Date Title
FI111519B (fi) Menetelmä sellaisen tabletin valmistamiseksi, joka sisältävää vaikuttavana aineena dikloorimetyleenifosfonihappoa
AU2001290354B2 (en) Pharmaceutical compositions comprising amlodipine maleate
EA004503B1 (ru) Фармацевтическая композиция леводопа/карбидопа/энтакапон
PL199779B1 (pl) Tabletka o dużej zawartości monosulfonianu 4-(4-metylopiperazyn-1-ylometylo)-N-[4-metylo-3-(4-pirydyn-3-ylo)pirymidyn-2-yloamino)fenylo]-benzamidu i sposób jej wytwarzania
AU2001290354A1 (en) Pharmaceutical compositions comprising amlodipine maleate
UA76417C2 (en) Pharmaceutical composition comprising immediate release phase and sustained release phase of paracetamol
CZ287558B6 (en) Pharmaceutical preparation
HU224983B1 (en) Swallow tablet comprising paracetamol
PL179080B1 (pl) Tabletka przeciwmigrenowa i sposób wytwarzania tabletki przeciwmigrenowej PL PL PL PL
CZ20033340A3 (en) Swallow tablet comprising paracetamol
CA1294551C (en) Sustained release fluoride composition
AU756338B2 (en) Stabile compositions comprising levosimendan and alginic acid
JPS5940134B2 (ja) 抗血栓性医薬組成物
US20060189565A1 (en) Pharmaceutical compositions of ganciclovir
CA1321752C (en) Products containing gallopamil and prazosin
CA1229552A (en) Cimetidine compositions
UA79567C2 (en) Orodispersible pharmaceutical composition of antithrombolic compound
AU2001100431A4 (en) Pharmaceutical compositions comprising amlodipine maleate
RU2221565C2 (ru) Фармацевтическая композиция, обладающая противотуберкулезной активностью, и способ ее получения
MXPA03001206A (es) Preparacion solida altamente absorbible.
KR20030070594A (ko) 암로디핀 말레에이트를 포함하는 약학 조성물

Legal Events

Date Code Title Description
HC Name/ company changed in application

Owner name: ROCHE DIAGNOSTICS GMBH

PC Transfer of assignment of patent

Owner name: RIEMSER ARZNEIMITTEL AG

MA Patent expired